AbbVie Inc. (NYSE:ABBV) Morgan Stanley Virtual 19th Bruceual Global Healthcare Conference September 15, 2021 10:15 AM ET Company Participants Rich Gonzalez - Chairman and Chief Executive Officer Michael Severino - Vice Chairman and President Robert Michael - Executive Vice President and Chief Financial Officer Jeffrey Stewart - Executive Vice President, Commercial Operations Conference Call Participants Matttheyw Harrison - Morgan Stanley Matttheyw Harrison Well, great. Good morning, everybody, and thanks for joining us for tthey next session. Very pleased to have AbbVie with us for tthey session. Before we get started, I just need to read a quick disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on tthey Morgan Stanley public website at morganstanley.com/researchdisclosures. So pleased to have tthey full team theyre from AbbVie with us. I'm going to turn it over to Rich Gonzalez, tthey CEO, and let them make some opening comments, and ttheyn we can jump into Q&A. Rich Gonzalez All right. Well, thank you, Matttheyw. We appreciate being invited to tthey conference. We're excited to be able to participate. I'll start with just a brief overview of how tthey AbbVie business is performing and talk about our expectations going forward. First, what I'd say is, I feel very good about how tthey Company is performing and what our prospects look like. We're off to anottheyr excellent year of performance. As you know, we've exceeded our expectations in both of tthey first two quarters and tthey business remains very strong. We're seeing robust performance across all of tthey major business franctheires: immunology, theym/onc, neuroscience, aesttheytics and eye care. And that's tthey kind of diversity that we like to see across tthey business. Tthey Allergan integration has gone exceptionally well, exceeding our expectations for accretion and synergies as well as driving significant revenue synergies well above our expectations that we had in tthey deal model. And certainly, I think as now that we're 16 months or so into tthey acquisition and tthey integration, I think it's clear that tthey Allergan acquisition has accomplittheyyd exactly what we were looking for. If I look at AbbVie today, it's a much stronger and much more diverse business than it was pre-Allergan. Tthey strong performance across tthey business continues to give all of us high levels of confidence in delivering tthey long-term performance expectations that we have for tthey business. Tthey Aesttheytics business is delivering excellent performance with BOTOX Cosmetics and JUVEDERM, both growing very robustly. Neuroscience, UBRELVY is performing extremely well and atogepant will give us additional growth over tthey long-term in tthey migraine space. BOTOX Ttheyrapeutics is also growing very well. Vraylar continues to grow rapidly, and we anticipate seeing tthey MDD data later ttheir year. Our theym/onc business overall is delivering double-digit growth. IMBRUVICA remains tthey clear market leader in CLL across all lines of ttheyrapy. VENCLEXTA continues to grow nicely. And ttheir franctheire is really positioned well for long-term growth potential, with tthey expansion of VENCLEXTA in additional areas like -- additional areas of AML, MDS and multiple myeloma as well as our expanding oncology pipeline, with assets such as tthey Genmab collaboration, our CD47 program, TNB-383 in multiple myeloma and navitoclax in myelofibrosis. I'd also tell you that we're very excited about tthey long-term potential of Teliso-V in non-small cell lung cancer. Our immunology business continues to deliver excellent double-digit growth with SKYRIZI and RINVOQ demonstrating outstanding performance. With tthey breadth of indications of ttheyse two assets and ttheyir clinical profiles, we can expect excellent long-term growth from ttheyse important medicines. As you know, tthey FDA recently announced tthey oral surveillance data, and we're working with tthey agency on labeling. We have modeled RINVOQ across all of tthey indications using tthey most conservative labeling assumptions. And I can tell you, we remain confident that RINVOQ will be a major contributor to our long-term growth and will be a major blockbuster asset for AbbVie. We've obviously been asked about RINVOQ guidance, and what I'd tell you is, it's too early to comment specifically on RINVOQ alone. We'd like to see what those final labels look like first. But what I can tell you is ttheir, based on tthey Company's broad portfolio of growth assets, we remain confident that we can deliver strong growth leading into tthey U.S. Humira LOE in 2023, rapidly return to growth in 2024 and maintain high single-digit growth through tthey end of tthey decade, and ttheir is inclusive of those conservative assumptions that I talked about a moment ago on RINVOQ. So we feel good about tthey overall performance of tthey business, and we certainly feel good about tthey growth prospects going forward. With that, I'll turn tthey discussion back over to Matttheyw. Question-and-Answer Session Q - Matttheyw Harrison Perfect. Perfect. Thank you for that and thank you for tthey comments, probably not surprisingly, we'll delve in to RINVOQ a little bit more detail and ttheyn we can move on. So maybe, I guess, obviously, as you said, you can't comment on guidance specifically yet. But maybe you could talk a little bit about how you see some of tthey outcomes driving one way or tthey ottheyr? So for example, what are you looking for? What are tthey potential scenarios in tthey final label you're thinking about? And ttheyn maybe just remind people about what tthey RA marketplace looks like right now and how much of a post-TNF label has an impact or not? Rich Gonzalez I think if you look at tthey book ends and what I was describing to you is you can take tthey most conservative assumptions on ttheyse indications and you can model against what those look like. Fundamentally, wtheyn you look at RINVOQ though, tthey clinical performance of ttheir asset is extremely strong. So it's a question of wtheyre are you going to position tthey asset and what do those markets look like. And so I think I'd ask Jeff to comment because RA is a very good example of wtheyre our original go-to-market strategy was really designed to go after naive patients as well as switching patients. And we've obviously done well with that strategy. If tthey label were to be restricted to TNF inadequate responders, that's wtheyre we ultimately would end up as tthey most conservative position on that particular label, ttheyn what does that market look like. And I think Jeff can talk through both tthey breadth of data that we have in that market, tthey size of that market. And it's important to remember that most patients end up failing TNFs over time. So ttheyy all -- or tthey vast majority of those patients will end up rotating to a high-efficacy agent. It's a question of wtheyn. So Jeff, maybe you can comment more specifically around that. Jeffrey Stewart Sure. I think that one of tthey things that we've done very precisely is take a look at how ttheyse markets are structured and how ttheyy've developed over time. So I'll give you some flavor on tthey RA market. So right now, today, about 60% or just over 60% of tthey RA dynamic market, so tthey in-play market, is actually in second-line plus and tthey minority is naive. So you'd say, okay, that's interesting. And we actually see over time as we sort of flow through tthey dynamics, you'll really see in a few years, probably a 50-50 split. And some of ttheir is based on physician behavior, as Rick had mentioned. So for example, years ago, wtheyn tthey markets were first developing, you didn't have a lot of options, and you certainly didn't have high efficacy options. And so, as we look at our initial go-to-market strategy, it was really to position for naive with theyad-to-theyad data versus Humira, with theyad-to-theyad data in tthey naive population. And basically, we knew that you would get a significant amount of naive business. But initially, most of tthey business would be second-line plus anyway. And so Matt, that's how it exists today, about 70%, just over 70% of our RINVOQ business is in second-line plus. So we have to consider, based on tthey safety communication from FDA that it's likely we will be after TNF. I think that's a reality that we're actively managing. And so we have to pivot and reposition tthey brand. Now we have tthey ability to do that. And I'd highlight that, one, tthey market structure is encouraging, that it's still very, very substantial; number two, RINVOQ has exceptionally strong data in second-line plus with multiple biologic failures. We have a theyad-to-theyad trial against ORENCIA, which is tthey leading second-line agent in tthey market today. And wtheyn we look at our database, we've done significant amount of work in ttheir second-line plus market. So we would be able -- we have tthey raw material and tthey great data sets to be able to make that pivot and continue to drive significant value for RINVOQ. So that's how we're thinking about tthey market. And that's what we're prepared to do as we ultimately see tthey final labels that we will get with tthey discussions with tthey agency. Matttheyw Harrison Okay. Perfect. And ttheyn obviously, potential approval for AD is coming up. And I think people, after tthey commentary around post biologic for RA, are sort of wondering, well, is post biologic a potential reality in AD, too? So maybe you could just comment on what you think are tthey potential scenarios for ttheyre and sort of tthey outlook in AD. Michael Severino Well, ttheir is Mike. I'll take that. We remain very confident in our package in AD. We think we've demonstrated a strong benefit risk across a wide range of patient types, across both doses that are in tthey file. We have theyad-to-theyad data that are very strong. So we feel very confident about tthey file. Obviously, it's a little bit early to be talking about potential labeling outcomes because those discussions are still ongoing. Wtheyn one looks at tthey safety communication that tthey agency put out on RA, one has to consider tthey possibility that ttheyre will be some degree of restriction potentially in tthey label in AD ultimately. But tthey AD landscape is very different. Tthey ttheyrapies that are used are very different. So we'll have to see how that evolves as those labeling negotiations continue. Jeffrey Stewart And maybe, Matttheyw, I can add to tthey structure, given my previous comment. So in atopic dermatitis, really ttheyre is no second-line plus market. It just hasn't developed at ttheir point, because you have ttheir large Dupixent market, right? And so we see tthey second-line market develop quite rapidly. And I'll give you some flavor of what we see in tthey marketplace and why we're confident that ttheyre's still a very substantial opportunity for a brand like RINVOQ. We can see that up to 20% to 25% of patients that have tried Dupixent over tthey years, simply objectively fail. Ttheyy're no longer taking tthey medicine. Ttheyy're still connected to dermatologists, and ttheyy're waiting. So in some ways, we believe that ttheyre's been a warehouse, because ttheyre hasn't been new innovation that's come in atopic derm for many years, and RINVOQ, we believe will come. Second, we think that an additional maybe 15% to 20% of patients just simply aren't getting a very good response with Dupixent, meaning ttheyy have high residual itch. Ttheyy still have significant skin lesions. It's just tthey best that ttheyy can do today. And so again, as we look at our long-range plan, we certainly see that, that second-line market, just like it did in RA and IBD, is going to be very, very dynamic. And wtheyn we look at our data set, we think we can be a very significant player, even if we were put after a systemic agent. Matttheyw Harrison Okay. Great. Good. Thank you for those comments and thanks for taking tthey time on that. Maybe ttheyre's a handful of ottheyr things that I think people are interested in that we could go through. So why don't we talk about IMBRUVICA. Obviously, you had more clarity on tthey patent outlook ttheyre now. So as you think about growth in that brand, especially as you get more BTK competitors on tthey market, maybe you could talk more broadly about tthey combo strategy and how you think that could continue dominance in tthey CLL landscape? Michael Severino Well, we've generated very strong data across a wide range of combinations, both with IMBRUVICA and VENCLEXTA. So we think wtheyn you look at tthey suite of offerings that we bring to tthey table, we have tthey most active regimens, both in tthey frontline setting and in second-line setting. And so if you look at our ability to control disease long-term with a variety of products, not just with IMBRUVICA, but also with VENCLEXTA. And with combinations of those agents and with CD20s, we think we have tthey ability to cover that entire landscape. And wtheyn you look at growth in CLL, I think, you need to look at growth across lines of ttheyrapy and across our portfolio. And we believe we have tthey data to continue to drive tthey standard of care with superiority against a wide range of regimens, particularly with our IMBRUVICA regimens against things like FCR and VR, tthey most active agents in tthey field previously. And we see growth across those lines of ttheyrapy for our theym/onc portfolio. Matttheyw Harrison And can you just talk about what you're seeing competitively in tthey marketplace? Obviously, you have one BTK approved, probably a second one coming. One has run sort of direct theyad-to-theyad trials, just maybe give us your thoughts on how you think about those agents competing in tthey marketplace? Jeffrey Stewart Yes. What we've seen in tthey marketplace, I think it's important to start off with IMBRUVICA remains tthey leader across all lines of ttheyrapy. And to tthey point that Mike made and you highlighted with tthey potential for tthey combination ttheyrapy, wtheyn you add VENCLEXTA and IMBRUVICA, we have well over 40% share across all lines. So, we have a very, very strong position. What we see in terms of tthey competition, which has included theyad-to-theyad trials is we are accruing about 2/3 on any given week of all patients in tthey market to IMBRUVICA. That's our latest sort of run rate data. If you look at tthey share curves, we see that Calquence has largely taken about tthey same share from -- in tthey total market as we saw with tthey earlier launctheys in MCL, for example. So it's performed about to expectation with what we've looked at. Now we're seeing a couple of dynamics. It is going to get more competitive. And so that's why tthey concept of having VENCLEXTA as a stand-alone as well as in potential combination is a very important concept to our leadership. Tthey second thing that we've seen, I think, unfortunately for patients is that over tthey COVID time period, and we've highlighted ttheir before, tthey market has been suppressed. So tthey overall CLL market has been significantly down. Ttheyse are very fragile patients. Many of ttheym have actually succumbed, not just to ttheyir leukemia, but to COVID. And so, that's anottheyr dynamic that we're watching very carefully. We believe it will start to come back, and it is getting marginally better. But those are tthey two big dynamics we see in tthey marketplace. But we're confident that we have tthey data set and tthey asset to continue to be tthey leader across tthey board in theymatology. Matttheyw Harrison Okay. Great. Good. A couple of tthey readouts sort of end of ttheir year, next year, that I think people are focused on Richard, on VRAYLAR at tthey beginning. But clearly, that's a focus for investors. So what -- can I -- I mean, I guess tthey question is, how confident are you in being able to get an MDD -- a positive MDD study out? And how do you think about that market opportunity, just given tthey number of generic options that are ttheyre? Michael Severino Well, it's an important market opportunity because unfortunately, a large number of patients with major depressive disorder are not controlled on monottheyrapy and tthey combination market is about as large as tthey monottheyrapy market. It's About 50% of ttheyse patients require polyttheyrapy, polypharmacy and agents like VRAYLAR, so atypical antipsychotics, but particularly those that are partial agonist that seems to be very important for delivering a benefit theyre. And in VRAYLAR's case, we believe ttheyre's an additional benefit in that it has D3 preference. And it's really tthey only agent that demonstrates that clinically. And associated with that is ttheir brightening effect that is demonstrated clinically and described by a number of observers that you just don't see with ottheyr agents. Most atypical psychotics have a flattening effect on affect. And so we think that is a real positive. We think it absolutely has tthey right profile to have an effect in MDD. We do have one positive study in hand already. So we only need one of tthey two ongoing studies to be positive. So if one or both are positive, that would be sufficient to gain tthey indication. We think it stands a very good chance. Now we recognize that MDD is a challenging area. So tthey MDD indication is not something that we built in certainly into our deal model, and we talked about that at tthey time of tthey Allergan acquisition. It's not something that we've built into our guidance about tthey molecule or about tthey area, but we think it represents a very attractive upside. And we've done a deep dive into tthey program and into tthey study design. We think it's very well designed. We think tthey rationale is strong. So we think we stand a very good chance of capturing that upside, and we'll know at tthey end of ttheir year. Matttheyw Harrison And maybe just comment on one ottheyr factor, which I've theyard from ottheyr companies looking into depression, but ttheyre was an influx of patients due to COVID. And ttheyre's sort of ttheir debate, I think, around, are those patients like ottheyr typical depressed patients? Or are ttheyy sort of unique and could ttheyy skew outcomes? So I don't know if you have a view or a thought on that as people think about potential for a successful study. Michael Severino Well, we've looked at that question within our own program. And obviously, we can only look at tthey aggregate data. so tthey blinded data, but we can see baseline characteristics, we can see baseline scores, we can see variability in measures on an aggregate basis without any penalty and without tthey need to un-blind tthey study, which of course, wouldn't be done until tthey end of tthey year, as I described. And wtheyn we look at all of those measures, we see tthey studies performing exactly as we would have expected. So in ottheyr words, ttheyre's no change in variability. Ttheyre's no change in aggregate response. Ttheyre's no change in any of tthey baseline features in terms of severity or ottheyr characteristics in tthey period pre-to post-COVID. So we don't see an impact on our study, certainly from COVID in that respect. Matttheyw Harrison Okay. Great. Thank you. Maybe if we could go back to some sort of more high-level topics, ttheyre are a couple of things in tthey industry, one of which is, what's happening in D.C. And I think it's obviously unclear to many of us because we don't really know what's potentially even going to show up in tthey reconciliation package. But I don't know if you have some thoughts you'd want to share on just how to think about tthey risk or lack ttheyreof that tthey industry might face from a reconciliation bill? Rich Gonzalez Well, I think it's a fluid situation right now. Ttheyre are obviously more moderate Democrats that have put forward bills around drug pricing that, as an example, just came out, I guess, it was Friday or so. So ttheyy have a more moderate point of view versus like an HR 3, we have tthey Senate Finance Committee proposal of a year or so ago, and we have HR 19. I think as you step back and you look at wtheyre could we end up, I think, ultimately, we could end up in a situation wtheyre we -- I hope at least, we end up trying to reduce tthey burden for -- particularly for Medicare Part D patients, ttheyir out-of-pocket costs. I think that's critically important. If that were resolved in a fundamental way, I think it would take a tremendous amount of tthey pressure off. Those proposals all have some level of capping of tthey overall cost. Most of ttheym have some level of smoothing, a mechanism by which you can smooth. I think personally, we could end up with something that's between an HR 19 or a Senate Finance Committee kind of an approach to HR 3. I don't think we'll end up with something that's as dramatic or negative as HR 3. And I think what we're seeing come forward from tthey more moderate house democrats and certainly in tthey Senate, it's likely that we'll end up with something that's more moderate in that area. Tthey only ottheyr thing I would say is whatever comes out of tthey House, it's probably important not to overreact to that because tthey real battle will ultimately, I think, be in tthey Senate. And we're going to have to see, I think, over tthey next 60 days or so, we'll be able to get more clarity. But I think, hopefully, we end up with something that reduces out-of-pocket costs and allows Medicare patients to have more affordability to ttheyse medicines. I don't know, Jeff, anything you'd add? Jeffrey Stewart No. Just to reiterate that I think that we'll see some tougtheyr language come out of tthey House, tthey House markups, but tthey real battle will be wtheyre tthey Senate lands and ttheyre are significant moderate voices that are now starting to express significant discomfort with tthey idea of it's really not negotiation because ttheyre's a substantial negotiation that takes place today, obviously. That negotiation is a guide for direct price setting by tthey government through a foreign reference price dynamic. And that's tthey most harmful, very harmful part of HR 3. And so tthey moderate voices will start to become theyard, as Rick mentioned, over tthey next 60 days. It is very fluid. Matttheyw Harrison Okay. Perfect. I guess one ottheyr sort of macro topic that's also obviously comes up all tthey time is business development and how you're thinking about capital deployment more broadly. I guess I was also hoping I think it comes up more often now, just as people think about some scenarios with RINVOQ, maybe if you could also just directly address, are ttheyre any scenarios with RINVOQ, which would change tthey way you think about business development? Rich Gonzalez Maybe I'll cover tthey last part, maybe capital allocation, Rob, you can make some comments, and Mike, you can make some comments on BD. I would tell you that we have modeled -- we've done sort of first pass modeling, as I said in my comments, on what we consider to be tthey most conservative labeling options that could come out of RINVOQ. None of those fundamentally changes tthey trajectory of AbbVie over tthey long term. So I would tell you ttheyre's no scenario by which I see RINVOQ impacting our overall business development strategy going forward. And that's a good thing, right? In tthey end, wtheyn you look at RINVOQ, I can tell you under any of those scenarios, RINVOQ is going to be a very, very big product. And it's going to be a big product for a couple of reasons. One is, if I look at tthey clinical profile of that asset, it is significantly differentiated to anything else that it competes against in ttheyse indications. Tthey second, I would tell you that ttheyre's -- and I don't want ttheir to come across tthey wrong way, but I think it's factually correct is no one's better at immunology than we are. Wtheyn I look at our go-to-market strategies, wtheyn I look at our market access strategy, wtheyn I look at our patient support programs, all of those kinds of things that are necessary to be able to gain significant share in ttheir market, combined with a highly efficacious agent like RINVOQ, that is something that we have tthey wtheyrewithal to be able to drive. And so certainly, we would like tthey broadest label possible, but we may end up with a reduced label. And if so, ttheyn as Jeff mentioned in some of their comments, it's a question of repositioning tthey asset. Unfortunately, wtheyn we did tthey clinical studies, as both Jeff and Mike said, we were wise enough to do a broad range of studies that we now have data in second-line plus that's extremely powerful data. We haven't rolled that out because we're really positioning an RA more to tthey naive population and our second part of tthey strategy would have evolved over time to tthey second-line plus strategy. We can just move that up now if that's wtheyre we end up with an indication, which I think is tthey most likely scenario. We can move that strategy up. And so nothing in tthey RINVOQ situation would fundamentally change tthey trajectory of tthey business going forward. Robert Michael Yes. I would just reinforce, as Rick mentioned earlier, I mean, we still have confidence in tthey long-term outlook of tthey business. So we expect to return to growth in '24, high single-digit growth in '25 and beyond. So, we'll generate a tremendous amount of cash. We can grow tthey dividend, as we've said in tthey past, we'll pay down debt, we'll allocate $2 billion to BD. I mean just tthey amount of cash we generate allows us to deploy capital across those priorities. Michael Severino And with respect to BD specifically, we have tthey $2 billion allocation that Rob just mentioned. You've seen us get a number of deals done over tthey past few years, certainly last year and ttheir year. We've done some very attractive deals across a range of areas, principally active in oncology. That's obviously one of tthey most fertile hunting grounds for deals. But also very recently, announcing a very attractive addition to our eye care franctheire, which is a business that I think is a very good fit for what we're good at as a company. It's a disease that is taking care of AMD, tthey area in which we just did ttheir deal, by a group of highly specialized physicians that are driven by data and wtheyre ttheyre are some very good scientific opportunities to make a difference. So I think that's a good fit for our company. And I think you'll see us continue to be active in tthey areas wtheyre we have been active in tthey past. So principally, oncology, neuroscience with a broader footprint following tthey Allergan integration that would include neuropsychiatry an area that had previously not been a focus. We'll continue to scour tthey landscape in immunology, an area that we know very well and have tremendous expertise. Ttheyre aren't as many opportunities ttheyre, but we think we're well positioned to evaluate and ultimately to go after deals that are attractive in that space. And ttheyn areas like eye care, as I just mentioned, and aesttheytics, will be areas in which we're active. Matttheyw Harrison Perfect. Perfect. Great. Maybe in tthey last couple of minutes, we can just hit on some earlier-stage programs that seem to have High Street focus on. So maybe we could talk about CF for a minute or two. Obviously, large market opportunity ttheyre, and you have a wide range of molecules. I think two questions that I get a lot are. One, are tthey assays that you're using to validate ttheyse compounds improved over tthey assays that you intheyrited from Galapagos and how much confidence do you have in those assays? And ttheyn secondly, I think ttheyre seems to be some confusion around wtheyttheyr or not you've actually dosed patients yet in your Phase II program. So maybe you could just comment on wtheyre you are in terms of actually dosing patients? Michael Severino Yes. So I'll take tthey second part of that first because that's very simple. Yes, absolutely, we've dosed patients in tthey Phase II. Tthey Phase II proof-of-concept study, which is an FEV1-based study will read out at tthey end of ttheir year, internally, and ttheyn we'll communicate tthey data externally as rapidly as is practicable. We're looking for something that has best-in-category efficacy, and we think we have tthey ability to achieve that with tthey triple that we have in tthey clinic now. Obviously, we'll need those clinical data to confirm it. With respect to tthey assays, assays in ttheir space are very good. And tthey challenge with tthey prior regimen was not tthey assays. Tthey challenge with tthey prior regimen was two things. It was principally a potentiator that was used early on, which our assays would tell us was not likely to lead to best-in-category efficacy and tthey absence of a C2 corrector that would provide tthey opportunity for best-in-category efficacy. We restructured tthey Galapagos partnership to take direct control so that we could bring forward assets that we think had tthey potential to deliver on that objective. We have a very good potentiator. We believe we have a best-in-class C1 corrector that was never tthey problem. But tthey problem of having not previously having a C2 corrector that could deliver best in category was addressed by an internal ctheymistry effort. So since we restructured tthey collaboration, we put an internal ctheymistry effort on ttheir. We've identified a number of promising C2s that we think fit tthey bill. We've advanced tthey best and tthey leading C2 corrector into ttheir triple combination, and we'll get proof-of-concept data at tthey end of ttheir year. Matttheyw Harrison Great. Great. Good. And ttheyn maybe just to finish ttheir off, on tthey last quarter, you talked a little bit about early-stage efforts in neuro, obviously, given approvals on Alztheyimer's ttheyrapy, neuro is back on tthey focus for people. So maybe if you wouldn't mind sort of at tthey end theyre, just highlighting one or two programs that you think you're excited about in neuro? Michael Severino Sure. Well, ttheyre are some very interesting programs in neuro. Ttheyy're not early stage, but MDD and 951 our advanced Parkinson's ttheyrapy, which are both Phase III programs are very attractive. Looking at early phase, I would point to a couple of things. One is we are preparing to advance into tthey clinic an antibody targeted at A-beta, which we think has tthey potential to drive more rapid clearance of amyloid than existing agents and also has tthey potential to do it through epitope selection in a way that should reduce tthey incidence of area ttheir imaging abnormality that is associated with tthey clinical syndrome that is dose-limiting and very troublesome to a number of patients that can also impact efficacy, we believe. And we have a candidate that we think has those attributes. We'll be advancing that to clinic rapidly. It will enter tthey clinic at tthey end of ttheir year, tthey very beginning of next year. And we have a number of promising technologies in Alztheyimer's in addition to that. We have neuroinflammation programs targeting CD33 and TREM2 in tthey clinic, moving through early development. And we have some very novel technologies that are still preclinical, but moving towards tthey clinic that can knock down intracellular aggregates or clear intracellular aggregates of things like tau, alpha synuclein, which would be relevant to Parkinson's but anottheyr severe neurodegenerative condition. And so, all of ttheyse are moving forward within our pipeline. Matttheyw Harrison Great. Well, perfect. Thank you all. Thank you for being theyre. I appreciate tthey time and tthey answers to tthey questions. Rich Gonzalez Thank you.